Navigation Links
SPX Completes Acquisition of Anhydro
Date:7/21/2010

CHARLOTTE, N.C., July 21 /PRNewswire-FirstCall/ -- SPX Corporation (NYSE: SPW) today announced that it has completed the acquisition of the Anhydro business, a Soeborg, Denmark-based global supplier of liquid concentration equipment, powder processing solutions, and dewatering plants and equipment.  The terms of the transaction were not disclosed.

Anhydro supplies a wide range of evaporation and drying solutions for dairy, food, and starch producers and for the chemical and pharmaceutical industries worldwide.  The transaction includes all Anhydro's business units with the exception of its Danish Filter business, Simatek A/S, and its German, U.K. and U.S. operations, as well as certain individual projects. The acquired business units employ 225 employees and are expected to generate 2010 full-year revenue of approximately 85 million Euros.

"The addition of Anhydro broadens our technology equipment offerings and systems capabilities and strengthens our ability to serve customers in the global food, pharmaceutical and chemical processing end markets," said SPX Chairman, President and Chief Executive Officer Christopher J. Kearney. "This strategic transaction also builds on our recent acquisition of Gerstenberg Schroder and underscores our commitment to expanding our Flow Technology segment, which remains a key component of our global growth strategy."

SPX first announced that it had entered into a definitive agreement to acquire Anhydro on June 18, 2010.  Anhydro will operate within SPX's Flow Technology segment.

About SPX

SPX Corporation (NYSE: SPW) is a Fortune 500 multi-industry manufacturing leader that provides its customers with highly-specialized, engineered solutions to solve critical business issues.

SPX products and technologies play an important role in the expansion of global infrastructure to help meet increased demand for power and energy and support many different sources of power generation, including coal and natural gas, nuclear, solar and geothermal. The company's innovative product portfolio, containing many energy efficient products, includes cooling systems for power plants throughout the world; highly advanced food processing components and turnkey, scalable systems serving the global food and beverage industry; process equipment that assists a variety of flow processes including oil and gas exploration, distribution and refinement and power generation; handheld diagnostic tools that aid in vehicle maintenance and repair; and power transformers that allow utility companies to regulate electric voltage, transmission and distribution.

With headquarters in Charlotte, North Carolina, SPX has 15,000 employees in more than 35 countries worldwide. Visit www.spx.com.

Certain statements in this press release including any statements relating to post-acquisition results, may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. Please refer to our public filings for a discussion of certain important factors that relate to forward-looking statements contained in this press release. The word "expect," "believe" and similar expressions may identify forward-looking statements. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Statements in the press release speak only as of the date of this press release, and SPX disclaims any responsibility to update or revise such statements.


'/>"/>
SOURCE SPX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016 Homozygous Familial Hypercholesterolemia (HoFH) ... Global Markets Direct,s latest Pharmaceutical and ... (HoFH) – Pipeline Review, H2 2016, provides ... (HoFH) (Metabolic Disorders) pipeline landscape. Homozygous ... is caused due to mutation from both ...
(Date:12/6/2016)... Dec. 6, 2016 Human Vaccines Market: ... region wise and country wise analysis of the ... manufacturers of human vaccines products, raw material suppliers, ... enter the market. The report provides qualitative ... market. Qualitative analysis comprises market dynamics, trends, product ...
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million ... suffer from the epidemic of diabetes. 1 However, ... persistently elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... serious complications, including cardiovascular events. If left untreated, hyperglycemia ... and eye disease or blindness. 3 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, ... is painful for her. "This is why the co-inventor and I have designed a ... They then created a prototype of the patent-pending AV-AIR, a device that serves as ...
(Date:12/7/2016)... ... XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... Man’s ... Filamentous Dermatitis Associated with Borrelia Infection” reveals that a condition similar ... the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease is ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Facial plastic ... this holiday season by donating a portion of proceeds to two local organizations: North ... Chicago Animal Control & Friends is a team of authorized and trained volunteers ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
Breaking Medicine News(10 mins):